ADAMs (a disintegrin and metalloproteinases) are involved in various biological events such as cell adhesion, migration and invasion, membrane protein shedding and proteolysis. However, there have been no systematic studies on the expression of ADAMs in human ovarian carcinomas. We therefore examined mRNA expression of all the proteolytic ADAM species including ADAM8, 9, 10, 12, 15, 17, 19, 20, 21, 28, 30, 33 and ADAMDEC1 in human ovarian carcinomas, and found that prototype membrane-anchored ADAM9m, but not secreted isoform ADAM9s, is significantly over-expressed in carcinomas than in control non-neoplastic ovarian tissue. Among 1 These subtypes show distinct differences not only in microscopic appearance but also in clinical behavior and molecular background.
standard platinum-and taxane-based chemotherapy for ovarian carcinomas. 3, 4 Although the incidence rate of clear cell carcinoma in Western countries is low ranging from 1% to 12%, 3, 5 clear cell carcinoma is the second most common subtype (15%-25%), 3, 6 following serous carcinoma (36%) in Japan. 6 Clear cell carcinoma patients at an advanced stage or with recurrent carcinoma usually take an unfavorable course mainly because of chemoresistance, 3, 4, 7 which is explained by mechanisms such as decreased drug accumulation, increased drug detoxification, and increased DNA repair activity. [7] [8] [9] [10] However, the details underlying resistance to chemotherapy in clear cell carcinoma have not been clarified.
Members of the ADAM (a disintegrin and metalloproteinase)
gene family are multifunctional proteins and involved in various pathophysiological events such as cell adhesion and migration, cell fusion, angiogenesis, and cancer cell proliferation and progression. [11] [12] [13] They are composed of 13 proteolytic ADAMs and eight non-proteolytic ADAMs. [11] [12] [13] Proteolytic ADAMs are transmembrane proteins comprising propeptide, metalloproteinase, disintegrin-like, cysteinerich, epidermal growth factor (EGF)-like, transmembrane and cytoplasmic domains, and share the metalloproteinase domain with that of matrix metalloproteinases. 11, [13] [14] [15] Some of the members such as ADAM9, ADAM12 and ADAM28 have short-secreted splice variants besides prototype membrane-anchored forms: ADAM9s and ADAM9m (ADAM9-L), 16 ADAM12s and ADAM12m (ADAM12-L), 17 and ADAM28s and ADAM28m. 18 Previous studies on human ovarian carcinomas showed over-expression of ADAM10, 19 ADAM12 20 and ADAM17. 21 ADAM10 and ADAM17 are reported to have a key role in shedding of the adhesion molecule L1 (CD171) and heparin-binding EGF-like growth factor (HB-EGF), respectively. 19, 21 ADAM12 is associated with clinical variables and poor prognosis of patients with high-grade serous ovarian carcinoma. 20 Expression of ADAM9 in ovarian carcinomas, albeit not significantly different from control, is also described without any comments on the function. 21 However, there have been no systematic studies on the expression profiles of ADAM family members in human ovarian carcinomas that are classified to histological subtypes. In addition, little or no information is available for the involvement of ADAM species in chemoresistance in ovarian carcinomas.
In the present study, we examined mRNA expression of all the proteolytic ADAM members in human ovarian carcinoma tissues, and found that only ADAM9m is significantly over-expressed in ovarian carcinomas, showing the highest expression in clear cell carcinoma. Our in vitro experiments also provided data that ADAM9m is involved in resistance to cisplatin in clear cell carcinoma cells.
| MATERIALS AND METHODS

| Clinical samples and histology
Ovarian tumor samples (n = 48) from patients with primary ovarian carcinoma and control ovarian tissues (n = 13) stored in the 
| RT-PCR and quantitative real-time PCR (qPCR)
cDNAs were prepared from isolated total RNA, and subjected to RT-PCR for examination of the 13 proteolytic ADAM species and housekeeping gene b-actin (Table S1 ) as described previously. 18 Relative expression levels of ADAM9m, ADAM10, ADAM15, ADAM17, ADAM28m and ADAM28s to b-actin were measured by qPCR with TaqMan probes (ABI Prism7000 Sequence Detection System; Applied Biosystems, Foster City, CA, USA) (Table S2) . Although the primers for ADAM9 by qPCR detected both ADAM9m and ADAM9s, the data were considered to reflect ADAM9m expression as no or negligible expression of ADAM9s was found in all the ovarian carcinoma tissues examined by RT-PCR.
| Immunohistochemistry
Paraffin sections of the ovarian tissues were subjected to immunostaining with goat anti-human ADAM9 polyclonal antibody (AF939; R&D Systems, Minneapolis, MN, USA) or non-immune goat IgG (AB-108-C; R&D Systems) after blocking endogenous peroxidase and antigen retrieval by autoclaving, followed by reactions with biotinylated secondary antibody and 3-3 0 -diaminobenzidine. 18 Stable transfectants were selected as described previously. 
| Statistical analysis
Data between the two independent groups were determined by was observed in less than~50% of the carcinoma samples ( Figure 1 ).
In contrast, ADAM9m, ADAM10, ADAM15, ADAM17, ADAM28m
and ADAM28s were expressed in more than 70% of the carcinoma tissues, and the expression of these ADAM species appeared to be high in the carcinomas and only weak in the non-neoplastic ovarian tissues ( Figure 1 ). Thus, we further analyzed the expression levels of these ADAM species in a larger number of ovarian carcinoma and control ovarian tissues by qPCR.
| Over-expression of ADAM9m and its correlations with clinicopathological factors
Expression levels of ADAM9m, ADAM10, ADAM15, ADAM17, ADAM28m and ADAM28s were compared by setting the average level in the control samples as 1.0. Among the ADAM species examined, only the ADAM9m level was significantly 3.1-fold higher in the carcinoma tissues (3.11 AE 2.52; mean AE SD; n = 35) than in the control non-neoplastic ovarian tissues (1.00 AE 0.40; n = 7) (P < .01) (Figure 2A ). Expression level of ADAM28m appeared to be higher in the carcinoma samples (4.14 AE 4.94; n = 30) than in the control samples (1.00 AE 0.64; n = 7), although no significant difference was obtained between the two groups (P = .068) (Figure 2A) . Expression levels of ADAM10, ADAM15, ADAM17 and ADAM28s were almost similar between the carcinoma and the control non-neoplastic samples (Figure 2A ). Therefore, we further analyzed ADAM9m expression levels by focusing on the four histological subtypes of ovarian carcinomas. As shown in Figure 2B and Table S3 , the level in the clear cell carcinomas (4.52 AE 2.79; n = 13), all the samples of which expressed ADAM9m, was the highest, and significantly higher than that in the control group (1.00 AE 0.40; n = 7). The levels were also significantly higher in the endometrioid (2.22 AE 0.93; n = 6) and mucinous carcinomas (3.68 AE 3.51; n = 5), but not in the serous carcinomas (1.67 AE 1.19; n = 11), than in the control group ( Figure 2B ; Table S2 ). Expression of ADAM9m was significantly~2-fold higher in the clear cell carcinomas (4.52 AE 2.79; n = 13) than in the nonclear cell carcinomas (2.27 AE 1.97; n = 22) (P < .01) ( Figure 2C ).
ADAM9m expression level was also significantly higher in Grade 3 ovarian carcinomas (3.91 AE 2.69; n = 17) than in Grade 1/2 carcinomas (2.36 AE 2.16; n = 18) (P < .05) (Table S3) . However, no positive correlations were observed between the expression levels of ADAM9m, ADAM10, ADAM15, ADAM17, ADAM28m and ADAM28s and clinicopathological parameters including age at operation, vascular and/or lymphatic invasion, lymph node metastasis, MIB1-positive cell index and clinical stages of the disease (Table S3 and data not shown for ADAM10, ADAM15, ADAM17, ADAM28m or ADAM28s). In contrast, overall survival tended to be shorter in the ADAM9m-high patient group than in the ADAM9m-low group (log-rank test, P = .0594; Figure S1 ). When intensity score, membrane score and total score of ADAM9m were compared among the histological subtypes, all the scores appeared to be higher in the clear cell carcinomas ( Figure 4A, C,E). Intensity, membrane and total scores were significantly higher in the clear cell carcinomas than in the non-clear cell carcinomas (P < .05 or P < .001) ( Figure 4B,D,F) . Total score of the ADAM9m immunostaining was also significantly higher in the G3 ovarian carcinomas compared with the G1/2 carcinomas (P < .01) (Table S4) .
However, there were no significant differences of the immunostain- 
| Knockdown, blocking or over-expression of ADAM9m and their influences on cisplatin resistance in ovarian clear cell carcinoma cell lines
As clear cell carcinoma is commonly resistant to platinum-based chemotherapy, 3, 7 we studied the possible involvement of ADAM9m on cisplatin resistance using human ovarian clear cell carcinoma cell lines, RMG-I and TOV21G cells. They expressed ADAM9m, ADAM10 and ADAM17, but not ADAM9s ( Figure 5A ). Figure 5B), although no changes in the expression of ADAM10 or ADAM17 were seen ( Figure 5A ). We first examined cell migration and EGFR phosphorylation, and found that cell migration activity was significantly increased in shRNA transfectants of both RMG-I and TOV21G cells compared with Mock transfectants ( Figure 5C ).
In contrast, EGFR phosphorylation was significantly decreased in RMG-I sh1 and RMG-I sh2 cells compared with Mock transfectants ( Figure 5D ). A similar finding was seen in TOV21G sh1 and TOV21G sh2 cells, although no significant difference was obtained with the TOV21G sh2 cells ( Figure 5D ).
When these cells were treated with cisplatin at LD50 concentra- Figure 6D ).
| DISCUSSION
In the present study, we have shown, to the best of our knowledge, Expression of phosphorylated EGFR (pEGFR) and EGFR was examined by immunoblotting. All assays were carried out in triplicate, and repeated 3 times. Bars, mean value AE SD. **P < .01; ***P < .001; NS, not significant. ADAM, a disintegrin and metalloproteinase tumors (carcinosarcomas) and undifferentiated carcinomas and all of them are aggressive, having a very high frequency of TP53 muta- ADAM9s play distinct roles in carcinoma cell migration by inhibiting and promoting the migration, respectively. 16 In the present study, we confirmed the inhibitory effect of ADAM9m on cell migration.
ADAM9s is known to enhance adhesion of A549 lung adenocarcinoma cells to cultured endothelial cells and increase Matrigel invasion through binding to b1 integrin, showing the stimulative effect on cancer cell dissemination. 24 In the metastasis of colon carcinoma cells, ADAM9s expressed by hepatic stellate cells is reported to bind to a6b4 and/or a2b1 integrins of colon carcinoma cells and enhance carcinoma cell invasion through digestion of laminin in the liver. 40 One of the characteristics of ovarian clear cell carcinomas is relatively slow growth 3, 4 and disease is presented at early stages. reported by siRNA-driven ADAM9 knock-down experiments in prostate carcinoma cells. 44 The authors in the study suggested that ADAM9 plays a role in therapeutic resistance by altering E-cadherin and integrin expression. 44 In colorectal carcinoma cell lines, chemotherapy-induced activation of ADAM17 is known to contribute to chemoresistance to 5-fluorouracil by transactivation of EGF receptor (EGFR) through shedding of EGFR ligands such as transforming growth factor-a. 45 Shedding of HB-EGF by ADAM17, ADAM9 and/or ADAM10 is also suggested to be related to resistance to doxorubicin in bladder and lung carcinoma cells. 46 In addition, a recent study on stomach carcinoma cell lines provided evidence that ADAM9 plays a role in EGFR transactivation through shedding of EGFR ligands. 47 In the present study, we provided data that EGFR activation is down-regulated by knock-down of ADAM9m expression. We also showed that ADAM9m exists on clear cell carcinoma cell membranes in an activated form and showed that knock- 
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